Bibliography
- Guyatt
G, Rennie D, Meade MO, Cook, D. Users’ Guides to the Medical
Literature: A Manual for Evidence-Based Clinical Practice. Chapter 1.
Third Edition. 2015.
- Rothwell
PM. Treating individuals 2. Subgroup analysis in randomised controlled
trials: importance, indications, and interpretation. Lancet 2005; 365
(9454): 176-86.
- VanderWeele TJ, Knol MJ. Interpretation of subgroup analyses in
randomized trials: heterogeneity versus secondary interventions. Ann
Intern Med 2011;154:680e3.
- Sun
X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G.. How to use a
subgroup analysis: users’ guide to the medical literature. JAMA
2014;311:405e11.
- Thanarajasingam
G, Minasian LM, Baron F, et al. Beyond maximum grade: modernising the
assessment and reporting of adverse events in haematological
malignancies [published correction appears in Lancet Haematol. 2019
Mar;6(3):e121]. Lancet Haematol. 2018;5(11):e563‐e598.
- Bennett
CL, Tigue CC, Angelotta C, McKoy JM, Edwards BJ Adverse effects of
drugs used to treat hematologic malignancies: surveillance efforts
from the research on adverse drug events and reports project. Semin
Thromb Hemost. 2007;33(4):365‐372.
- Wittes
J. On looking at subgroups. Circulation . 2009;119(7):912‐915.
- Wang
R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in
medicine—reporting of subgroup analyses in clinical trials. N
Engl J Med . 2007;357(21):2189‐2194.
- Koch
A, Framke T. Reliably basing conclusions on subgroups of randomized
clinical trials. J Biopharm Stat . 2014;24(1):42‐57.
- Vidic
A, Chibnall JT, Goparaju N, et al. Subgroup analyses of randomized
clinical trials in heart failure: facts and numbers. ESC Heart Fail.
2016 Sep; 3(3): 152–157.
- Wijn
SRW, Rovers MM, Le LH, et al. Guidance from key organisations on
exploring, confirming and interpreting subgroup effects of medical
treatments: a scoping review. BMJ Open. 2019;9(8):e028751.
- Gil-Sierra
MD, Fénix-Caballero S, Abdel-Kader Martin L, et al. Checklist for
Clinical Applicability of Subgroup Analysis. J Clin Pharm Ther. 2020
Jun;45(3):530-538
- Oxman AD, Guyatt GH. A
consumer’s guide to subgroup analyses. Ann Intern Med 1992;116:78-84.
- Sun X, Briel M, Walter
SD, et al. Is a subgroup effect believable? Updating criteria to
evaluate the credibility of subgroup analyses. BMJ 2010;340:c117.
- Sun
X, Ioannidis JPA, Agoritsas T, et al. How to use a subgroup analysis.
JAMA 2014;311:405
- Sun
X, Briel M, Busse JW, et al. Subgroup Analysis of Trials Is Rarely
Easy (SATIRE): a study protocol for a systematic review to
characterize the analysis, reporting, and claim of subgroup effects in
randomized trials. Trials. 2009;10:101.
- Sun
X, Briel M, Busse JW, et al. Credibility of claims of subgroup effects
in randomised controlled trials: systematic review. BMJ.
2012;344:e1553.
- Moher
D., Liberati A., Tetzlaff J, et al. Group P. Preferred reporting items
for systematic reviews and meta-analyses: The PRISMA statement. Int.
J. Surg. 2010;8:336–341.
- Oxman
AD. Subgroup analyses. BMJ 2012;344:e2022.
- Higgins JPT, Thomas J, Chandler
J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook
for Systematic Reviews of Interventions version 6.0 (updated July
2019). Cochrane, 2019. Available from
www.training.cochrane.org/handbook.
- Primo
J, Escrig J. MetaSurv: Excel calculator for survival meta-analyzes.
2008. Avaialble in:
http://www.redcaspe.org/herramientas/descargas/MetaSurv.xls
- Brookes
ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup
analyses in randomized trials: risks of subgroup-specific analyses;
power and sample size for the interaction test. J Clin Epidemiol 2004;
57: 229–236.
- Assmann SF, Pocock SJ, Enos LE, Kasten LE.. Subgroup analysis and
other (mis) uses of baseline data in clinical trials. Lancet 2000;
355: 1064–1069.
- Feinstein
AR. The problem of cogent subgroups: a clinicostatistical tragedy. J
Clin Epidemiol 1998; 51: 297–299.
- Moreira
ED Jr, Stein Z, Susser E. Reporting on methods of subgroup analysis in
clinical trials: a survey of four scientific journals. Braz J Med Biol
Res. 2001;34(11):1441‐1446.
- Zhang
S, Liang F, Li W, Hu X. Subgroup Analyses in Reporting of Phase III
Clinical Trials in Solid Tumors. J Clin Oncol .
2015;33(15):1697‐1702.
- Schulz
KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised trials. Int J Surg.
2011;9(8):672‐677.
- Mistry
D, Patel S, Hee SW, Stallard N, Underwood M. Evaluating the quality of
subgroup analyses in randomized controlled trials of
therapist-delivered interventions for nonspecific low back pain: a
systematic review. Spine (Phila Pa 1976) 2014;39:618e29.
- Saragiotto
BT, Maher CG, Moseley AM, et al. A systematic review reveals that the
credibility of subgroup claims in low back pain trials was low. J Clin
Epidemiol. 2016;79:3‐9.